Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?

Gemcitabine is a deoxycytidine analogue that has a broad spectrum of antitumour activity in many solid tumours including pancreatic cancer. We have recently carried out a pharmacogenomic study in cancer patients treated with gemcitabine, and found that one genetic polymorphism of an enzyme involved...

Descripción completa

Detalles Bibliográficos
Autores principales: Ueno, H, Kiyosawa, K, Kaniwa, N
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Minireview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360307/
https://www.ncbi.nlm.nih.gov/pubmed/17595663
http://dx.doi.org/10.1038/sj.bjc.6603860
_version_ 1782153016381538304
author Ueno, H
Kiyosawa, K
Kaniwa, N
author_facet Ueno, H
Kiyosawa, K
Kaniwa, N
author_sort Ueno, H
collection PubMed
description Gemcitabine is a deoxycytidine analogue that has a broad spectrum of antitumour activity in many solid tumours including pancreatic cancer. We have recently carried out a pharmacogenomic study in cancer patients treated with gemcitabine, and found that one genetic polymorphism of an enzyme involved in gemcitabine metabolism can cause interindividual variations in the pharmacokinetics and toxicity of this agent. In this paper, we review recent genetic studies of gemcitabine, and discuss the possibility of individualised cancer chemotherapy based on a pharmacogenomic approach.
format Text
id pubmed-2360307
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23603072009-09-10 Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy? Ueno, H Kiyosawa, K Kaniwa, N Br J Cancer Minireview Gemcitabine is a deoxycytidine analogue that has a broad spectrum of antitumour activity in many solid tumours including pancreatic cancer. We have recently carried out a pharmacogenomic study in cancer patients treated with gemcitabine, and found that one genetic polymorphism of an enzyme involved in gemcitabine metabolism can cause interindividual variations in the pharmacokinetics and toxicity of this agent. In this paper, we review recent genetic studies of gemcitabine, and discuss the possibility of individualised cancer chemotherapy based on a pharmacogenomic approach. Nature Publishing Group 2007-07-16 2007-06-26 /pmc/articles/PMC2360307/ /pubmed/17595663 http://dx.doi.org/10.1038/sj.bjc.6603860 Text en Copyright © 2007 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Minireview
Ueno, H
Kiyosawa, K
Kaniwa, N
Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?
title Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?
title_full Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?
title_fullStr Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?
title_full_unstemmed Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?
title_short Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?
title_sort pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?
topic Minireview
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360307/
https://www.ncbi.nlm.nih.gov/pubmed/17595663
http://dx.doi.org/10.1038/sj.bjc.6603860
work_keys_str_mv AT uenoh pharmacogenomicsofgemcitabinecangeneticstudiesleadtotailormadetherapy
AT kiyosawak pharmacogenomicsofgemcitabinecangeneticstudiesleadtotailormadetherapy
AT kaniwan pharmacogenomicsofgemcitabinecangeneticstudiesleadtotailormadetherapy

Ejemplares similares